JURA Bio and Syena partner to develop TCR-based therapies
JURA Bio will receive development, regulatory and commercial milestone payments along with tiered deferred option payments.
Company News
Novo Holdings acquires biopharma company Paratek for $462m
Glenmark Pharma to divest 75% stake in life sciences unit for $680m
Debiopharm, SunRock sign agreement for cancer ADCs
Kezar and Everest enter lupus nephritis therapy development deal
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
EC grants approval for Menarini’s breast cancer therapy
AbCellera and Regeneron expand antibody discovery collaboration
